CMS Proposes Additional Payment for Shockwave’s Coronary IVL in Hospital Inpatient Cases

Go back to CMS Proposes Additional Payment for Shockwave’s Coronary IVL in Hospital Inpatient Cases

NTAP Proposed for C2 in Coronary 'A Win' for Shockwave Medical (SWAV) - Canaccord Genuity

April 28, 2021 10:40 AM EDT

Canaccord Genuity analyst William Plovanic reiterated a Buy rating and $149.00 price target on Shockwave Medical (NASDAQ: SWAV), saying the proposed use of New Technology Add-On Payment (NTAP) for coronary IVL cases by the The Centers for Medicare and Medicaid Services... More